• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian journal of ophthalmology >Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis.
【24h】

Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis.

机译：不含防腐剂的人工泪液中局部用2％环孢素A治疗春季角膜结膜炎。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: A double-masked, placebo-controlled trial to evaluate the short-term efficacy and safety of topical 2% cyclosporine A in preservative-free artificial tears for patients with vernal keratoconjunctivitis. Methods: Twenty patients with severe vernal keratoconjunctivitis were included in the study. All were treated with topical 2% cyclosporine A eye drops. One eye of each patient was administered 2% cyclosporine A in preservative-free artificial tears; the fellow eye received the placebo (vehicle) for the first 2 weeks, in a double-masked, placebo-controlled trial. Thereafter, the placebo eye received cyclosporine A (open trial). Symptoms and signs were scored on the day of enrolment and at the end of week 2, 4, and 14. Results: At the end of week 2, no statistically significant decrease was noted from baseline in mean scores of either signs (p = 0.18) or symptoms (p = 0.50) in the eyes that received placebo. On the other hand, a statistically significant decrease was observed in both sign and symptom scores (p 0.001, for both) of eyes that received cyclosporine A. Significant differences were also noted at 2 weeks in mean scores of both signs and symptoms (p 0.001, for both) between the eyes that received cyclosporine A and those that received placebo. At week 4 and 14, statistically significant decreases in both sign scores and symptom scores were noted compared with baseline in the eyes that received cyclosporine A and in the eyes that had initially received placebo (p 0.001, for all). Interpretation: Topical 2% cyclosporine A in preservative-free artificial tears is effective in alleviating signs and symptoms of patients with severe vernal keratoconjunctivitis and had no observed side effects over the course of the study.
机译：背景：一项双重掩盖的安慰剂对照试验，用于评估局部2％环孢素A在无防腐剂的人工泪液中对春季角膜结膜炎患者的短期疗效和安全性。方法：本研究纳入了20例严重的春季角膜结膜炎患者。全部用局部2％环孢素A滴眼液治疗。每位患者的一只眼睛在不含防腐剂的人工泪液中施用2％环孢素A;在双重掩盖的安慰剂对照试验中，另一只眼睛在前两周接受了安慰剂（媒介物）。此后，安慰剂眼接受环孢菌素A（开放试验）。在入组当天和第2、4和14周结束时对症状和体征进行评分。结果：在第2周结束时，任一体征的平均评分均未见基线上的统计学显着下降（p = 0.18 ）或接受安慰剂的眼睛出现症状（p = 0.50）。另一方面，接受环孢霉素A的眼睛的症状和症状评分均出现统计学显着性下降（两种情况，p <0.001）。在第2周，症状和体征的平均得分也显着降低（p接受环孢菌素A的眼睛和接受安慰剂的眼睛之间的均<0.001。在第4周和第14周，与接受环孢菌素A的眼睛和最初接受安慰剂的眼睛相比，与基线相比，在体征评分和症状评分上均出现统计学上显着的下降（对于所有患者，p <0.001）。解释：不含防腐剂的人工泪液中局部用2％环孢素A可以有效减轻严重春季角结膜炎患者的体征和症状，并且在研究过程中未观察到任何副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号